Current status of robotic partial nephrectomy in Japan

Area of Science:

• Urology
• Surgical Oncology
• Medical Technology

Background:

• Robot-assisted partial nephrectomy (RAPN) has demonstrated safety and efficacy in Western studies.
• Limited data exists on RAPN's application and outcomes within Japan.
• RAPN was not previously covered by Japanese public health insurance, restricting patient access.

Approach:

• A prospective clinical trial was conducted in Japan to evaluate the efficacy and safety of RAPN.
• The study aimed to gather data supporting the integration of RAPN into standard medical services.
• Techniques for RAPN as practiced in Japan were also reviewed.

Key Points:

• Favorable results from the clinical trial confirmed the efficacy and safety of RAPN in the Japanese population.
• The positive outcomes led to the approval of RAPN for public health insurance coverage in April 2016.
• This approval significantly improved accessibility to RAPN for all individuals in Japan, irrespective of their financial status.

Conclusions:

• Robot-assisted partial nephrectomy (RAPN) is a safe and effective procedure for kidney cancer treatment in Japan.
• The inclusion of RAPN in public health insurance has democratized access to advanced surgical care.
• This advancement marks a significant milestone in Japanese urological and oncological surgical practices.